ClinicalTrials.Veeva

Menu
Ascension | Sacred Heart Pensacola Oncology logo

Ascension | Sacred Heart Pensacola Oncology

Research site
About
Yazan Alsayed, M.D.; Alexander Brown, M.D.; Ranjith Dissanayake, M.D.; Dany El-Sayah, M.D.; Mose Hayes, M.D.; James Watkins, M.D.; Zachary Wright, M.D., F.A.C.P.

Site insights

Top conditions

Top treatments

Pembrolizumab
Lenalidomide
Bevacizumab
Sacituzumab
Carboplatin
Paclitaxel
Nivolumab
S0931
Ramucirumab
LEE011

Parent organization

This site is a part of Ascension

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

6 of 33 total trials

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY)

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with...

Enrolling
Relapsed/Refractory Follicular Lymphoma
Marginal Zone Lymphoma
Drug: Rituximab
Drug: Lenalidomide

This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment o...

Enrolling
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Biological: Pembrolizumab
Biological: Ramucirumab

This is a clinical study to compare the efficacy and safety of HBI-8000 combined with nivolumab to Placebo combined with nivolumab in patients with u...

Active, not recruiting
Progressive Brain Metastasis
Unresectable or Metastatic Melanoma
Drug: Placebo in combination with nivolumab
Drug: HBI-8000 in combination with nivolumab

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surg...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of phy...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vin...

Enrolling
Large B-cell Lymphoma
Drug: Golcadomide
Drug: Doxorubicin

Trial sponsors

SWOG Cancer Research Network logo
Celgene logo
National Cancer Institute (NCI) logo
ECOG-ACRIN Cancer Research Group logo
Gilead Sciences logo
Alliance for Clinical Trials in Oncology logo
Amgen logo
BeiGene logo
Bristol-Myers Squibb (BMS) logo
D

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems